Indications And Dose
Adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision) ▶BY MOUTH ▶Child 1–23 months: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg) ▶Child 2–11 years: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g) ▶Child 12–17 years: Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily ▶Adult: Initially 1 g once daily, alternatively initially 1 g daily in 2 divided doses, then increased in steps of 500 mg every week, adjusted according to response; usual dose 2–3 g daily; maximum 3 g per day ▶BY RECTUM ▶Child 1–23 months: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg) ▶Child 2–11 years: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g) ▶Child 12–17 years: Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily l UNLICENSED USE Granules not licensed for rectal use. Tablets not licensed to be crushed and dispersed in liquid. Vigabatrin doses in BNF publications may differ from those in product literature.
PDF page 371